Gyros Platform Integrated into Second, US-Based, Contract Research Organization
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Gyros AB confirmed that Radix BioSolutions, a US-based contract research organization specializing in custom assay development, reagent manufacturing, and a provider of assay services, will integrate a Gyrolab™ xP workstation into their immunoassay development programs.
Kerry Oliver, CEO at Radix Biosolutions explained the reasoning behind the decision, “The Gyros™ platform enables us to develop immunoassays more rapidly than any other approaches currently available. At Radix we differentiate ourselves by fostering strong relationships with our customers by meeting project requirements and timelines, and always striving to exceed expectations. Our scientists provide the experience and capabilities in reagent definition and production, robust assay development and validation, and the regulatory compliance required during the development of a customer’s therapeutic. It is essential for us to leverage leading edge technology at each stage of a project in order to best fulfill the unique needs of each customer.”
Erik Wallden, CEO at Gyros, added: “We are extremely pleased that Radix BioSolutions have recognized one of the key benefits of our immunoassay platform, namely rapid assay development. We also believe that their unique approach of making identified assay reagents commercially available will enable other Gyrolab xP workstation users working in GLP environments in the USA to procure quality controlled reagents from Radix for their own laboratory needs.”
Kerry Oliver, CEO at Radix Biosolutions explained the reasoning behind the decision, “The Gyros™ platform enables us to develop immunoassays more rapidly than any other approaches currently available. At Radix we differentiate ourselves by fostering strong relationships with our customers by meeting project requirements and timelines, and always striving to exceed expectations. Our scientists provide the experience and capabilities in reagent definition and production, robust assay development and validation, and the regulatory compliance required during the development of a customer’s therapeutic. It is essential for us to leverage leading edge technology at each stage of a project in order to best fulfill the unique needs of each customer.”
Erik Wallden, CEO at Gyros, added: “We are extremely pleased that Radix BioSolutions have recognized one of the key benefits of our immunoassay platform, namely rapid assay development. We also believe that their unique approach of making identified assay reagents commercially available will enable other Gyrolab xP workstation users working in GLP environments in the USA to procure quality controlled reagents from Radix for their own laboratory needs.”
